Avatrombopag

Chemical formula: C₂₉H₃₄Cl₂N₆O₃S₂  Molecular mass: 649.65 g/mol  PubChem compound: 9852519

Active ingredient description

Avatrombopag is an orally active, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
B02BX08 B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX08

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
DOPTELET Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
DOPTELET Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 570406-98-3
DrugBank Drug: DB11995
PubChem Compound: 9852519
RxNorm Ingredient: 2045726
SNOMED-CT Concept: 770717002
Avatrombopag (substance)
UNII Identifier: 3H8GSZ4SQL
AVATROMBOPAG

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.